Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970063 | 0.88 | NPC1 (0.52) | USP30KCNH2NPC1RAB9A | |
| SCHEMBL9970010 | 0.86 | HTR2B (0.51) | POLBMAPTSMN1; SMN2HCRTR1HCRTR2 | |
| Glasdegib SCHEMBL29359708 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18184932 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL22104131 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL24503991 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL2068480 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL27100349 | 0.85 | EPHX1 (0.45) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL2068016 | 0.84 | EPHX1 (0.44) | USP30KCNH2NPC1RAB9APOLB | |
| Glasdegib SCHEMBL29362720 | 0.84 | EPHX1 (0.44) | USP30KCNH2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147359-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10934256-B2 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10464897-B2 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, HRAS | USP30 1994/4885KCNH2 4623/4885NPC1 350/4885 |
| US-20210147359-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, SMO | USP30 1952/4885KCNH2 4494/4885NPC1 231/4885 |
| US-10934256-B2 | Compounds and methods for treating cancer | GLI1, SHH, HRAS | USP30 1994/4885KCNH2 4623/4885NPC1 350/4885 |
| US-10464897-B2 | Compounds and methods for treating cancer | GLI1, SHH, HRAS | USP30 1994/4885KCNH2 4623/4885NPC1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.